Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Dual route vaccination for plague with emergency use applications.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • معلومة اضافية
    • Author-Supplied Keywords:
      Dual route
      Emergency use
      Mucosal
      Plague
      Protection
      Systemic
      Vaccine
    • Abstract:
      Here, we report a dual-route vaccination approach for plague, able to induce a rapid response involving systemic and mucosal immunity, whilst also providing ease of use in those resource-poor settings most vulnerable to disease outbreaks. This novel vaccine (VypVaxDuo) comprises the recombinant F1 and V proteins in free association. VypVaxDuo has been designed for administration via a sub-cutaneous priming dose followed by a single oral booster dose and has been demonstrated to induce early onset immunity 14 days after the primary immunisation; full protective efficacy against live organism challenge was achieved in Balb/c mice exposed to 2 × 10 4 median lethal doses of Yersinia pestis Co92, by the sub-cutaneous route at 25 days after the oral booster immunisation. This dual-route vaccination effectively induced serum IgG and serum and faecal IgA, specific for F1 and V, which constitute two key virulence factors in Y. pestis , and is therefore suitable for further development to prevent bubonic plague and for evaluation in models of pneumonic plague. This is an essential requirement for control of disease outbreaks in areas of the world endemic for plague and is supported further by the observed exceptional stability of the primary vaccine formulation in vialled form under thermostressed conditions (40 °C for 29 weeks, and 40 °C with 75% relative humidity for 6 weeks), meaning no cold chain for storage or distribution is needed. In clinical use, the injected priming dose would be administered on simple rehydration of the dry powder by means of a dual barrel syringe, with the subsequent single booster dose being provided in an enteric-coated capsule suitable for oral self-administration. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Vaccine is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
    • Author Affiliations:
      1Department of Pure & Applied Chemistry, University of Strathclyde, Glasgow, UK
      2Proxima Concepts Ltd, London BioScience Innovation Centre, UK
      3Defence Science & Technology Laboratory, Porton Down, Salisbury UK
    • ISSN:
      0264-410X
    • Accession Number:
      10.1016/j.vaccine.2018.06.039
    • Accession Number:
      131199610
  • Citations
    • ABNT:
      MOORE, B. D. et al. Dual route vaccination for plague with emergency use applications. Vaccine, [s. l.], v. 36, n. 34, p. 5210–5217, 2018. DOI 10.1016/j.vaccine.2018.06.039. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=131199610&custid=s8280428. Acesso em: 12 ago. 2020.
    • AMA:
      Moore BD, New RRC, Butcher W, et al. Dual route vaccination for plague with emergency use applications. Vaccine. 2018;36(34):5210-5217. doi:10.1016/j.vaccine.2018.06.039
    • APA:
      Moore, B. D., New, R. R. C., Butcher, W., Mahood, R., Steward, J., Bayliss, M., Macleod, C., Bogus, M., & Williamson, E. D. (2018). Dual route vaccination for plague with emergency use applications. Vaccine, 36(34), 5210–5217. https://doi.org/10.1016/j.vaccine.2018.06.039
    • Chicago/Turabian: Author-Date:
      Moore, B.D., R.R.C. New, W. Butcher, R. Mahood, J. Steward, M. Bayliss, C. Macleod, M. Bogus, and E.D. Williamson. 2018. “Dual Route Vaccination for Plague with Emergency Use Applications.” Vaccine 36 (34): 5210–17. doi:10.1016/j.vaccine.2018.06.039.
    • Harvard:
      Moore, B. D. et al. (2018) ‘Dual route vaccination for plague with emergency use applications’, Vaccine, 36(34), pp. 5210–5217. doi: 10.1016/j.vaccine.2018.06.039.
    • Harvard: Australian:
      Moore, BD, New, RRC, Butcher, W, Mahood, R, Steward, J, Bayliss, M, Macleod, C, Bogus, M & Williamson, ED 2018, ‘Dual route vaccination for plague with emergency use applications’, Vaccine, vol. 36, no. 34, pp. 5210–5217, viewed 12 August 2020, .
    • MLA:
      Moore, B. D., et al. “Dual Route Vaccination for Plague with Emergency Use Applications.” Vaccine, vol. 36, no. 34, Aug. 2018, pp. 5210–5217. EBSCOhost, doi:10.1016/j.vaccine.2018.06.039.
    • Chicago/Turabian: Humanities:
      Moore, B.D., R.R.C. New, W. Butcher, R. Mahood, J. Steward, M. Bayliss, C. Macleod, M. Bogus, and E.D. Williamson. “Dual Route Vaccination for Plague with Emergency Use Applications.” Vaccine 36, no. 34 (August 16, 2018): 5210–17. doi:10.1016/j.vaccine.2018.06.039.
    • Vancouver/ICMJE:
      Moore BD, New RRC, Butcher W, Mahood R, Steward J, Bayliss M, et al. Dual route vaccination for plague with emergency use applications. Vaccine [Internet]. 2018 Aug 16 [cited 2020 Aug 12];36(34):5210–7. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=131199610&custid=s8280428